Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acinetobacter genomic species 13TU

Journal of Microbiology, Immunology and Infection

Volumn 45, Issue 2, 2012, Pages 108-112

  Liu, Yen Hung ^a   Kuo, Shu Chen ^a,b,c   Lee, Yi Tzu ^b,d   Chang, Ian C Y ^e   Yang, Su Pen ^a   Chen, Te Li ^a,b   Fung, Chang Phone ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d Chutung Veterans Hospital   (Taiwan)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Acinetobacter; GyrA; ParC; Quinolone resistance determining regions

Indexed keywords

ASPARAGINE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEUCINE; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; PROTEIN PARC; SERINE; TYROSINE;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER GENOMIC SPECIES 13TU; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENOME; BACTERIAL STRAIN; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SEQUENCE ANALYSIS;

ACINETOBACTER; ACINETOBACTER INFECTIONS; AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BACTEREMIA; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; QUINOLONES; SEQUENCE ANALYSIS, DNA; TAIWAN;

EID: 84859873809     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.09.001     Document Type: Article

References (33)

1. Joly-Guillou M.L. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005, 11:868-873.
2. Bergogne-Berezin E. The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents. J Hosp Infect 1995, 30(Suppl.):441-452.
3. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008, 21:538-582.
4. Vila J., Ruiz J., Goni P., Marcos A. Jimenez de Anta T. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1995, 39:1201-1203.
5. Vila J., Ribera A., Marco F., Ruiz J., Mensa J., Chaves J., et al. Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2002, 49:471-477.
6. Cho Y.J., Moon D.C., Jin J.S., Choi C.H., Lee Y.C., Lee J.C. Genetic basis of resistance to aminoglycosides in Acinetobacter spp. and spread of armA in Acinetobacter baumannii sequence group 1 in Korean hospitals. Diagn Microbiol Infect Dis 2009, 64:185-190.
7. Lin Y.C., Sheng W.H., Chen Y.C., Chang S.C., Hsia K.C., Li S.Y. Differences in carbapenem resistance genes among Acinetobacter baumannii, Acinetobacter genospecies 3 and Acinetobacter genospecies 13TU in Taiwan. Int J Antimicrob Agents 2010, 35:439-443.
8. Vila J., Ruiz J., Goni P., Jimenez de Anta T. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother 1997, 39:757-762.
9. Spence R.P., Towner K.J. Frequencies and mechanisms of resistance to moxifloxacin in nosocomial isolates of Acinetobacter baumannii. J Antimicrob Chemother 2003, 52:687-690.
10. Wisplinghoff H., Edmond M.B., Pfaller M.A., Jones R.N., Wenzel R.P., Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000, 31:690-697.
11. Jacoby G.A. Mechanisms of resistance to quinolones. Clin Infect Dis 2005, 41(Suppl. 2):S120-S126.
12. Nordmann P., Poirel L. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J Antimicrob Chemother 2005, 56:463-469.
13. Hopkins K.L., Davies R.H., Threlfall E.J. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents 2005, 25:358-373.
14. Wisplinghoff H., Decker M., Haefs C., Krut O., Plum G., Seifert H. Mutations in gyrA and parC associated with resistance to fluoroquinolones in epidemiologically defined clinical strains of Acinetobacter baumannii. J Antimicrob Chemother 2003, 51:177-180.
15. Lim Y.M., Shin K.S., Kim J. Distinct antimicrobial resistance patterns and antimicrobial resistance-harboring genes according to genomic species of Acinetobacter isolates. J Clin Microbiol 2007, 45:902-905.
16. Lee J.H., Choi C.H., Kang H.Y., Lee J.Y., Kim J., Lee Y.C., et al. Differences in phenotypic and genotypic traits against antimicrobial agents between Acinetobacter baumannii and Acinetobacter genomic species 13TU. J Antimicrob Chemother 2007, 59:633-639.
17. Lee Y.C., Huang Y.T., Tan C.K., Kuo Y.W., Liao C.H., Lee P.I., et al. Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes. J Antimicrob Chemother 2011, 66:1839-1846.
18. Chuang Y.C., Sheng W.H., Li S.Y., Lin Y.C., Wang J.T., Chen Y.C., et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis 2011, 52:352-360.
19. Chen T.L., Siu L.K., Wu R.C., Shaio M.F., Huang L.Y., Fung C.P., et al. Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii. Clin Microbiol Infect 2007, 13:801-806.
20. Chang H.C., Wei Y.F., Dijkshoorn L., Vaneechoutte M., Tang C.T., Chang T.C. Species-level identification of isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region. J Clin Microbiol 2005, 43:1632-1639.
21. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI document M100-S20 2010, Clinical and Laboratory Standard Institute, CLSI, Wayne, PA, USA.
22. Performance standards for antimicrobial susceptibility testing:11th informational supplement. NCCLS document M100-S11 2001, National Committee for Clinical Laboratory Standards, NCCLS, Wayne, PA, USA.
23. Bergogne-Berezin E., Towner K.J. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996, 9:148-165.
24. Sheng W.H., Wang J.T., Li S.Y., Lin Y.C., Cheng A., Chen Y.C., et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis 2011, 70:380-386.
25. Lee J.K., Lee Y.S., Park Y.K., Kim B.S. Mutations in the gyrA and parC genes in ciprofloxacin-resistant clinical isolates of Acinetobacter baumannii in Korea. Microbiol Immunol 2005, 49:647-653.
26. Higgins P.G., Fluit A.C., Milatovic D., Verhoef J., Schmitz F.J. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003, 21:409-413.
27. Valentine S.C., Contreras D., Tan S., Real L.J., Chu S., Xu H.H. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California. J Clin Microbiol 2008, 46:2499-2507.
28. Hamouda A., Amyes S.G. Novel gyrA and parC point mutations in two strains of Acinetobacter baumannii resistant to ciprofloxacin. J Antimicrob Chemother 2004, 54:695-696.
29. Higgins P.G., Coleman K., Amyes S.G. Bactericidal and bacteriostatic activity of gemifloxacin against Acinetobacter spp. in vitro. J Antimicrob Chemother 2000, 45(Suppl. 1):71-77.
30. Pestova E., Millichap J.J., Noskin G.A., Peterson L.R. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother 2000, 45:583-590.
31. Principles and practice of infectious diseases 2010, Chruchill livingstone, Philadephia. 7th ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
32. Kanematsu E., Deguchi T., Yasuda M., Kawamura T., Nishino Y., Kawada Y. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother 1998, 42:433-435.
33. Chiu C.H., Lee H.Y., Tseng L.Y., Chen C.L., Chia J.H., Su L.H., et al. Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactam and imipenem in Acinetobacter baumannii clinical isolates in Taiwan. Int J Antimicrob Agents 2010, 35:382-386.